Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Disease × Doxorubicin × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 31 Lymphoma 18 Lymphoma, Large B-Cell, Diffuse 17 Sarcoma 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 12 Neoplasm Metastasis 10 Hodgkin Disease 9 Lymphoma, Non-Hodgkin 8 Recurrence 7 Prostatic Neoplasms 7 Neoplasms 7 Multiple Myeloma 7 Burkitt Lymphoma 7 Ovarian Neoplasms 6 Leukemia 6 Lymphoma, B-Cell 5 Fallopian Tube Neoplasms 5 Cardiotoxicity 5 Carcinoma, Hepatocellular 5 Urinary Bladder Neoplasms 4 Osteosarcoma 4 Liver Neoplasms 4 Triple Negative Breast Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Pancreatic Neoplasms 3 Lymphoma, Follicular 3 Leukemia, Myeloid, Acute 3 Leukemia, Biphenotypic, Acute 3 Colonic Neoplasms 3 Waldenstrom Macroglobulinemia 2

Interventions

obinutuzumab 1 ioflupane 1 idelalisib 1 daratumumab 1 alovudine 1 Vindesine 1 Vincristine 1 Rituximab 1 Prednisone 1 Positron Emission Tomography Computed Tomography 1 Mitomycin 1 Magnetic Resonance Spectroscopy 1 Lenalidomide 1 Ga(III)-DOTATOC 1 Doxorubicin 1 Dexamethasone 1 Cyclophosphamide 1 Bleomycin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01659099 2018-03-07

GAINED

The Lymphoma Academic Research Organisation

Phase 3 Terminated

Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡